Zealand Pharma A/S is a Danish biotechnology research company, which designs and develops peptide-based medicines, mainly focusing on metabolic diseases like diabetes and obesity.

[4] Zealand Pharma A/S was founded by Bjarne Due Larsen, Lars Hellerung Christiansen, Leif Helth Jensen, Dan Buxbom, and Florian Schönharting in 1997 as Peptide Probe Technologies ApS, a biopharmaceutical company focused on the design and development of peptide-based medicine.

[5][6][7] In 1998, the company changed its name to Zealand Pharma ApS following the addition of several new members, including Eva Steiness and former Lundbeck personnel.

[14] Zealand Pharma is mostly known and recognized for the diabetes medication Lyxumia, which has been developed in collaboration with the French pharmaceutical company Sanofi.

Since 2014, Zealand Pharma has collaborated with the coronary care unit at Rigshospitalet in Copenhagen developing the medication Danegaptid, which should serve the purpose of preventing injuries in the tissue of the heart, frequently seen among angioplasty patients.